Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.
about
New developments in the management of chronic lymphocytic leukemia: role of ofatumumabClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaCD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.Management of chronic lymphocytic leukemia.The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysisSafety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trialTargeted therapy for chronic lymphocytic leukemia: current status and future directions.Ofatumumab for the treatment of chronic lymphocytic leukemia.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?The use of ofatumumab in the treatment of B-cell malignancies.Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateBendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Current Treatment of Chronic Lymphocytic Leukemia.Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia.Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL).Renal involvement in chronic lymphocytic leukemia
P2860
Q26768396-B8FC0D9D-6042-42CA-B8DC-6C2E42FAB106Q26783600-B08929A8-238E-4B9E-AD6E-A23197017CF0Q30383411-4950711A-20C1-4911-8F23-02BF979C8E39Q33695912-D00D4F84-B182-43AE-90ED-F3A0F4C64B72Q35040896-F26F283C-3B2A-4E6C-A4A5-552B18C0B225Q35953518-C31AA698-02FB-4D09-88E7-6F27DA79EC6AQ37267608-059F75B6-5E4F-48B1-ACDD-0464FB2BB093Q38331701-E9308EE5-9E12-4564-B29D-94C5BD65EC62Q38424862-E5656798-BE0F-4792-ACBF-E30FCC11E1A9Q38548134-44BBEC0B-F025-40A9-AF94-A64A1D33FB65Q38573785-B32C15BA-4199-4BD5-9C28-3720DB9EBC2FQ38586543-0228BAE2-C088-442F-B64D-5588534825EFQ38603992-C8E6B4D1-6847-4DE7-8FDB-E0FCDA1769E4Q38632940-E4E8D20F-7871-4BB9-9A54-0697CF74E9F0Q38642648-DCFA6457-E9EE-4518-8EC4-F313347386F9Q38676408-3273945F-E087-428A-88EA-CDA4A12A5837Q38818283-812CECEA-145C-4037-AC76-FE9DEDBC86C5Q38920650-14062114-311E-48A8-A622-B6ACFA6A7CC1Q39018189-69D4BAC6-46A8-46CD-9E72-D41AC3509E90Q39129372-53501432-FE61-4DB4-842F-2BD73F0D9B34Q40303819-69090A57-DDE7-4E08-B8B9-365C927800D2Q40736899-D25A3650-8F77-46EC-8E8E-8FA3CF2FB362Q41507971-68480BD7-0582-4BD7-9381-6CE6487374C5Q42660818-B8602C3B-02C6-4C1C-82E5-8062DA6E6949Q43135377-4E3D0381-45DC-4973-8878-3DC3DF1E746FQ43469341-CD44D903-70F5-47E7-ACB6-6F8E34D33D6EQ47887134-58736E1B-2AD0-48E5-9E3C-E2DA72D9A6B9Q52576558-4CC02867-71AE-4B2F-B2C0-73AEDB95753CQ54322737-D0C88CB8-7625-42A4-8FA9-857AD7A5601EQ55424824-3F1D3BB9-B149-4D33-9B25-2C28548DBDC0Q57053852-D7B06849-FECA-4575-9A08-B2A1226E97FC
P2860
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Bendamustine in combination wi ...... MA Multicenter Phase II Trial.
@en
Bendamustine in combination wi ...... MA Multicenter Phase II Trial.
@nl
type
label
Bendamustine in combination wi ...... MA Multicenter Phase II Trial.
@en
Bendamustine in combination wi ...... MA Multicenter Phase II Trial.
@nl
prefLabel
Bendamustine in combination wi ...... MA Multicenter Phase II Trial.
@en
Bendamustine in combination wi ...... MA Multicenter Phase II Trial.
@nl
P2093
P2860
P50
P356
P1433
P1476
Bendamustine in combination wi ...... EMA Multicenter Phase II Trial
@en
P2093
A M Liberati
A Piciocchi
D Vincenti
F Morabito
L Laurenti
P2860
P2888
P304
P356
10.1038/LEU.2013.334
P50
P577
2013-11-13T00:00:00Z
P5875
P6179
1041581221